Biogen

Nachrichten

Reuters - vor 8 Stunden

What to Watch in the Week Ahead and on Monday, July 29

What to Watch in the Week Ahead and on Monday, July 29 The Day Ahead is an email and PDF publication that includes the day's major stories and events, analyses and other features. To receive The Day Ahead, Eikon users can register at DAY/US . Thomson One users can register at RT/DAY/US. All times in ET/GMT ON MONDAY McDonald's is expected to post a smaller growth in second-quarter revenue as customers cut back on dining out amid persistent inflation.

Reuters - vor 8 Stunden

U.S. STOCKS Hartford Financial, Avantor, WesBanco

BUZZ-U.S. STOCKS ON THE MOVE-Hartford Financial, Avantor, WesBanco Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 Wall Street bounced back on Friday with the blue-chip Dow leading the charge as some megacap tech and chip stocks recovered from the week's pummeling, while a largely in-line key inflation reading kept bets of an early rate cut alive.

Reuters - vor 10 Stunden

U.S. STOCKS Saia, Ultra Clean, CBRE Group

BUZZ-U.S. STOCKS ON THE MOVE-Saia, Ultra Clean, CBRE Group Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 Wall Street bounced back on Friday as megacap tech and chip stocks recovered from the week's pummeling, while a largely in-line key inflation reading kept bets for an early start to interest-rate cuts alive.

Reuters - vor 13 Stunden

U.S. STOCKS Biogen, Newell Brands, Charter Communications

BUZZ-U.S. STOCKS ON THE MOVE-Biogen, Newell Brands, Charter Communications Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 U.S. stock index futures extended gains on Friday after in-line U.S. inflation data kept bets for an interest-rate cut by September intact.

Reuters - vor 14 Stunden

U.S. STOCKS Deckers Outdoor, Mohawk Industries, Insulet

BUZZ-U.S. STOCKS ON THE MOVE-Deckers Outdoor, Mohawk Industries, Insulet Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 Nasdaq futures jumped 1% on Friday as megacap tech and chip stocks bounced back after a drubbing earlier this week, while investors hoped for a further let-up in inflation in a crucial data release later in the day.

Reuters - vor 15 Stunden

Eisai Says It Will Seek Re-Examination Of CHMP Opinion

BRIEF-Eisai Says It Will Seek Re-Examination Of CHMP Opinion July 26 (Reuters) - EISAI- UPDATE ON REGULATORY REVIEW OF LECANEMAB FOR EARLY ALZHEIMER’S DISEASE IN THE EUROPEAN UNION UPDATE ON REGULATORY REVIEW OF LECANEMAB FOR EARLY ALZHEIMER’S DISEASE IN THE EUROPEAN UNION EISAI- WILL SEEK RE-EXAMINATION OF CHMP OPINION

Reuters - vor 15 Stunden

Eisai Co Ltd - Update On Regulatory Review Of Lecanemab For Early Alzheimer's Disease In The European Union

BRIEF-Eisai Co Ltd - Update On Regulatory Review Of Lecanemab For Early Alzheimer's Disease In The European Union July 26 (Reuters) - Eisai Co Ltd 4523.T : EISAI CO LTD - UPDATE ON REGULATORY REVIEW OF LECANEMAB FOR EARLY ALZHEIMER’S DISEASE IN THE EUROPEAN UNION EISAI CO LTD - EUROPEAN MEDICINES AGENCY HAS ADOPTED A NEGATIVE OPINION ON THE MARKE

Reuters - vor 15 Stunden

Biogen falls as EU regulator declines to recommend Alzheimer's drug

BUZZ-Biogen falls as EU regulator declines to recommend Alzheimer's drug ** Shares of drugmaker Biogen BIIB.O down 5.6% at $214.81 before the bell ** The European Union's drugs regulator rejected BIIB and Japan-based partner Eisai's 4523.T treatment for early Alzheimer's disease ** The agency's committee said it had recommended not granting an authorization as the observed benefits did not counterbalance the risk of serious side events, especially brain swelling and bleeding ** The drug, lecanem

Reuters - vor 15 Stunden

Alzheimer's drug from Eisai and Biogen rejected in Europe

UPDATE 7-Alzheimer's drug from Eisai and Biogen rejected in Europe EU regulator cites safety concerns, small benefit Eisai, Biogen to seek re-examination of decision The drug's launch in the U.S. has been slow Biogen shares fall 7%, rival Lilly slips 1% Adds Lilly and analyst comments, paragraph 21-22 By Manas Mishra and Puyaan Singh July 26 (Reuters) - The European Union's drugs regulator has rejected Eisai 4523.T and Biogen's BIIB.O Leqembi treatment for early Alzheimer's disease, saying the r

Reuters - vor 15 Stunden

EU medicines regulator rejects Eisai-Biogen Alzheimer's drug

EU medicines regulator rejects Eisai-Biogen Alzheimer's drug July 26 (Reuters) - The European Union's drugs regulator on Friday rejected Eisai 4523.T and Biogen's BIIB.O breakthrough treatment for early Alzheimer's disease, in a blow to the drugmakers as take-up in the United States has been slower than expected. Reporting by Manas Mishra and Puyaa

Reuters - vor 16 Stunden

EMA Says CHMP Recommended Not Granting Marketing Authorisation For Leqembi (Lecanemab)

BRIEF-EMA Says CHMP Recommended Not Granting Marketing Authorisation For Leqembi (Lecanemab) July 26 (Reuters) - Biogen Inc BIIB.O EMA SAYS CHMP EXTENSIONS OF INDICATION FOR 11 MEDICINES THAT ARE ALREADY AUTHORISED IN THE EU INCLUDING AREXVY EMA SAYS CHMP RECOMMENDED NOT GRANTING MARKETING AUTHORISATION FOR LEQEMBI (LECANEMAB) EMA SAYS CHMP RECOMME

Reuters - vor 3 Tagen

Sage shares decline on plans to scrap development of tremor drug

BUZZ-Sage shares decline on plans to scrap development of tremor drug Updates ** Shares of Sage Therapeutics SAGE.O fall ~ 1 7.5 % to $10.7 9 , its biggest one day loss pct since April ** Co, partner Biogen's BIIB.O oral experimental drug, SAGE-324, to treat essential tremors failed in a mid-stage study ** Co, BIIB do not plan to develop the drug f

Reuters - vor 3 Tagen

Sage shares decline on plans to scrap development of tremor drug

BUZZ-Sage shares decline on plans to scrap development of tremor drug ** Shares of Sage Therapeutics SAGE.O fall 19% to $10.60 premarket ** Co, partner Biogen's BIIB.O oral experimental drug, SAGE-324, to treat essential tremors failed in a mid-stage study ** Co, BIIB do not plan to develop the drug further but may consider it for other potential c

Reuters - vor 3 Tagen

Biogen and Sage to scrap neurological disorder drug development after trial failure

UPDATE 2-Biogen and Sage to scrap neurological disorder drug development after trial failure Adds share movement in paragraph 2, analyst comment in paragraph 4 July 24 (Reuters) - Biogen BIIB.O and Sage Therapeutics SAGE.O do not plan to conduct further studies for their neurological disorder drug after it failed in a mid-stage trial, the drugmakers said on Wednesday.

Reuters - vor 3 Tagen

Sage Therapeutics And Biogen Announce Topline Results From Phase 2 Kinetic 2 Study Of 324 (BIIB124) For The Treatment Of Essential Tremor

BRIEF-Sage Therapeutics And Biogen Announce Topline Results From Phase 2 Kinetic 2 Study Of SAGE-324 (BIIB124) For The Treatment Of Essential Tremor July 24 (Reuters) - Sage Therapeutics SAGE.O SAGE THERAPEUTICS AND BIOGEN ANNOUNCE TOPLINE RESULTS FROM PHASE 2 KINETIC 2 STUDY OF SAGE-324 (BIIB124) FOR THE TREATMENT OF ESSENTIAL TREMOR SAGE THERAPEU

Reuters - vor 3 Tagen

Biogen and Sage's neurological disorder drug fails in mid-stage trial

Biogen and Sage's neurological disorder drug fails in mid-stage trial July 24 (Reuters) - Biogen BIIB.O and Sage Therapeutics' SAGE.O neurological disorder drug failed in a mid-stage trial, the companies said on Wednesday. Reporting by Sriparna Roy in Bengaluru; Editing by Shilpi Majumdar

Reuters - vor 4 Tagen

Ionis Pharma rises on data from nerve disorder drug study

BUZZ-Ionis Pharma rises on data from nerve disorder drug study ** Shares of Ionis Pharmaceuticals IONS.O rise 5.7% to $50.53 ** Co says its experimental drug to treat a complex genetic disorder helped improve communication, cognition and motor function in an early-mid-stage study ** Angelman syndrome primarily affects the nervous system and is char

Reuters - vor 1 Woche

Sionna Therapeutics buys rights to AbbVie's cystic fibrosis therapies

Sionna Therapeutics buys rights to AbbVie's cystic fibrosis therapies July 16 (Reuters) - Sionna Therapeutics said on Tuesday that it has acquired the exclusive rights to develop and sell three of AbbVie's ABBV.N experimental therapies for cystic fibrosis, a potentially fatal genetic condition. WHY IT'S IMPORTANT The licensing deal with Abbvie expands the Boston, Massachusetts based startup's pipeline of experimental therapies being tested to treat the genetic condition that can clog lungs and t

Reuters - vor 2 Wochen

Novo owner backs Swiss biotech Asceneuron in $100 million round

Novo owner backs Swiss biotech Asceneuron in $100 million round By Maggie Fick LONDON, July 16 (Reuters) - Swiss biotech company Asceneuron said on Tuesday it had raised $100 million from investors including the controlling shareholder of Wegovy maker Novo Nordisk to fund clinical development of its Alzheimer's disease drug. The Series C round was led by Novo Holdings, the investment arm of the Novo Nordisk Foundation, which will hold a board seat on the Lausanne-based company.

Reuters - vor 2 Wochen

Nasdaq top and bottom performing stocks at about 03:45 p.m. EDT

BUZZ - Nasdaq top and bottom performing stocks at about 03:45 p.m. EDT Nasdaq 100 .NDX Top Performers Percent Change Charter Communications Inc CHTR.OQ +4.1% Baker Hughes Co BKR.OQ +4% Fastenal Co FAST.OQ +3.9% Diamondback Energy Inc FANG.OQ +3.7% Paychex Inc PAYX.OQ +2.7% Bottom Performers Percent Change Dollar Tree Inc DLTR.OQ -3.4% Biogen Inc BIIB.OQ -3.4% PDD Holdings Inc PDD.OQ -2.8% Lululemon Athletica Inc LULU.OQ -2.7% Starbucks Corp SBUX.OQ -2.5% The Nasdaq 100 .NDX gained 39.49 points,

Konditionen

Beliebte Finanzwerte

Rechtlicher Hinweis: Die Unternehmen der XM Group bieten Dienstleistungen ausschließlich zur Ausführung an sowie Zugang zu unserer Online-Handelsplattform. Durch diese können Personen die verfügbaren Inhalte auf oder über die Internetseite betrachten und/oder nutzen. Eine Änderung oder Erweiterung dieser Regelung ist nicht vorgesehen und findet nicht statt. Der Zugang wird stets geregelt durch folgende Vorschriften: (i) Allgemeine Geschäftsbedingungen; (ii) Risikowarnungen und (iii) Vollständiger rechtlicher Hinweis. Die bereitgestellten Inhalte sind somit lediglich als allgemeine Informationen zu verstehen. Bitte beachten Sie, dass die Inhalte auf unserer Online-Handelsplattform keine Aufforderung und kein Angebot zum Abschluss von Transaktionen auf den Finanzmärkten darstellen. Der Handel auf Finanzmärkten birgt ein hohes Risiko für Ihr eingesetztes Kapital.

Sämtliche Materialien, die auf unserer Online-Handelsplattform veröffentlicht sind, dienen ausschließlich dem Zweck der Weiterbildung und Information. Die Materialien beinhalten keine Beratung und Empfehlung im Hinblick auf Finanzen, Anlagesteuer oder Handel und sollten nicht als eine dahingehende Beratung und Empfehlung aufgefasst werden. Zudem enthalten die Materialien keine Aufzeichnungen unserer Handelspreise sowie kein Angebot und keine Aufforderung für jegliche Transaktionen mit Finanzinstrumenten oder unverlangte Werbemaßnahmen für Sie zum Thema Finanzen. Die Materialien sollten auch nicht dahingehend aufgefasst werden.

Alle Inhalte von Dritten und die von XM bereitgestellten Inhalte sowie die auf dieser Internetseite zur Verfügung gestellten Meinungen, Nachrichten, Forschungsergebnisse, Analysen, Kurse, sonstigen Informationen oder Links zu Seiten von Dritten werden ohne Gewähr bereitgestellt. Sie sind als allgemeine Kommentare zum Marktgeschehen zu verstehen und stellen keine Anlageberatung dar. Soweit ein Inhalt als Anlageforschung aufgefasst wird, müssen Sie beachten und akzeptieren, dass der Inhalt nicht in Übereinstimmung mit gesetzlichen Bestimmungen zur Förderung der Unabhängigkeit der Anlageforschung erstellt wurde. Somit ist der Inhalt als Werbemitteilung unter Beachtung der geltenden Gesetze und Vorschriften anzusehen. Bitte stellen Sie sicher, dass Sie unseren Hinweis auf die nicht unabhängige Anlageforschung und die Risikowarnung im Hinblick auf die vorstehenden Informationen gelesen und zur Kenntnis genommen haben, die Sie hier finden.

Biogen

Nachrichten

Konditionen

Beliebte Finanzwerte

XM Live-Chat